Meflynate Xl

Methylphenidate hydrochloride, the active ingredient in Meflynate Xl, is a central nervous system stimulant presented as an oral formulation for oral use. It is prescribed for the management of attention deficit hyperactivity disorder (ADHD) and narcolepsy in children, adolescents, and adults.

GNH USA supplies Meflynate Xl as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable sourcing for regulated markets across the EU and other regions.

Meflynate Xl (methylphenidate) is used in central nervous system stimulant therapy for neurobehavioral disorders, primarily targeting attention regulation and wakefulness.

- Attention deficit hyperactivity disorder (ADHD): reduces hyperactivity, improves attention and impulse control in children, adolescents, and adults. - Narcolepsy: decreases excessive daytime sleepiness and cataplexy episodes, supporting sustained wakefulness.

Meflynate Xl may cause a range of adverse reactions. Patients should be aware of both frequent and less common events.

Common Side Effects: - Insomnia: difficulty falling or staying asleep. - Decreased appetite: reduced hunger leading to weight loss. - Headache: mild to moderate cranial pain. - Stomach pain: gastrointestinal discomfort. - Increased heart rate: tachycardia or palpitations. - Irritability: mood changes or agitation.

Serious or Rare Side Effects: - Cardiovascular events: hypertension, arrhythmia, or chest pain. - Psychosis: hallucinations or delusional thinking. - Severe allergic reactions: rash, swelling, or anaphylaxis. - Motor or vocal tics: involuntary movements or sounds. - Growth suppression: reduced height or weight gain in children. - Priapism: prolonged, painful erection.

Before prescribing Meflynate Xl, clinicians should evaluate several safety considerations.

- Cardiovascular assessment: evaluate blood pressure and cardiac history prior to initiation. - Psychiatric monitoring: watch for new or worsening anxiety, mood swings, or psychotic symptoms. - Growth monitoring: in pediatric patients, track height and weight regularly. - Potential for abuse: prescribe only when benefits outweigh the risk of dependence. - Drug interactions: review concomitant medications for stimulant interactions. - Store at ambient temperature: keep below 25 °C, in the original container, protected from moisture and light.

Meflynate Xl can interact with other medicines, requiring careful review.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Sympathomimetic agents (e.g., pseudoephedrine): may cause severe hypertension. - Tricyclic antidepressants: increased cardiovascular toxicity.

Moderate Interactions (Monitor Closely): - Antihypertensives: may reduce blood‑pressure‑lowering effect. - Anticonvulsants (e.g., carbamazepine): may lower methylphenidate plasma levels. - Selective serotonin reuptake inhibitors (SSRIs): may increase rare risk of serotonin syndrome.